Pharma Point: Hepatitis B Therapeutics in Major Developed Markets to 2015 – Worldwide Industry Research, Analysis, Size, Shares, and Forecast to 2021
Incidence tends to be higher in countries with a significant number of migrants from medium and high-prevalence countries. Approximately 350 million people worldwide are infected with chronic hepatitis B, which causes significant morbidity and mortality. Around 780,000 patients die from hepatitis B each year, of which 650,000 deaths are due to complications such as cirrhosis and liver cancer. Despite this, diagnosis and treatment rates are poor, stemming from its asymptomatic nature.
View full press release